Coumadin No Worse for Mental Function Than Pradaxa, When Well AdministeredDecember 20th 2022
Pradaxa (dabigatran) and Coumadin (warfarin) came out even in this randomized study. The Brazilian researchers who conducted the study said one explanation for the result is that use of Coumadin was exceptionally well managed because the patients were enrolled a study.
Discontinuation Rates for Biosimilars Are High But Similar to Rates for Reference BiologicsSeptember 15th 2022
The review focused on Remicade (infliximab) and Enbrel (etanercept). The annualized discontinuation rate was 21% among patients who had undergone nonmedical switching to biosimilars. However, the rates were similar to those found in some separate analyses of patients on reference biologics.
What Biosimilar Interchangeability Status Would Mean for PharmacistsNovember 16th 2021
There is now a mad scramble to gain interchangeable status for biosimilars, but the meaning and significance of this appellation haven't yet been worked out for health care consumers or the manufacturing community.
Studies Reveal Positive Results for Infliximab BiosimilarJune 18th 2020
In studies presented this month at the European E-Congress of Rheumatology 2020, investigators revealed positive findings for the infliximab biosimilar CT-P13 (Inflectra, Remsima), which is developed by Celltrion of Incheon, Republic of Korea.